- Lilly advances retatrutide toward sleep-apnea marketEli Lilly is moving its triple-agonist drug retatrutide closer to a potential launch for sleep-apnea. The company, which expects to introduce the drug for obesity next year, is now gathering data i…
- Biotech reverse mergers surge in 2026, reaching highest level since 2021 as PIPE financing spikesBiotech companies are using reverse mergers to re‑enter public markets at a rate not seen since 2021, according to a J.P. Morgan report released in October 2026. In the first nine months of 2026,…